Summary

The global market for Gene Therapies for Cancer Treatment was estimated to be worth US$ 8230 million in 2024 and is forecast to a readjusted size of US$ 30409 million by 2031 with a CAGR of 18.5% during the forecast period 2025-2031.
Cancer gene therapy is an innovative treatment approach that involves directly modifying the patient's genome to treat cancer. Common strategies include Chimeric Antigen Receptor T-cell (CAR-T) therapy, gene editing technologies such as CRISPR-Cas9, and viral vector-mediated gene transduction. Compared to traditional chemotherapy and radiotherapy, gene therapies offer higher specificity and personalized advantages by repairing or replacing oncogenes at the molecular level, activating the immune system to recognize and eliminate tumor cells, or enhancing anti-tumor immune responses. Cancer gene therapies are applicable to various cancer types, including hematologic malignancies (such as leukemia and lymphoma) and solid tumors (such as lung and breast cancer). Although challenges remain, such as high costs, manufacturing complexities, and long-term efficacy, the demonstrated effectiveness in clinical trials positions gene therapy as a significant research direction in oncology.

The cancer gene therapy market is rapidly evolving, driven by several key factors: First, the rising incidence of cancer and the limitations of traditional treatments have increased the demand for novel therapeutic options. Second, advancements in gene editing and cell engineering technologies have made the development and production of cancer gene therapies more feasible. Third, supportive policies from regulatory agencies regarding personalized and precision medicine have created a favorable environment for the clinical application of gene therapies. Fourth, patients' focus on efficacy and quality of life has driven the demand for innovative treatments. Additionally, collaborations between biopharmaceutical companies and research institutions have accelerated the translation of technologies and product development.
Despite the significant potential of cancer gene therapies, several challenges and risks persist. First, the high treatment costs, involving personalized cell processing and gene editing, increase the burden on patients and healthcare systems. Second, the manufacturing process is complex, encompassing cell collection, gene modification, expansion, and reinfusion, with any deviation potentially impacting efficacy and safety. Third, the long-term efficacy and potential side effects are not yet fully understood, requiring more clinical data for validation. Fourth, the regulatory approval processes are cumbersome and time-consuming, potentially delaying the market introduction of new therapies. Fifth, the market is highly competitive, with numerous companies and research institutions investing in R&D, leading to increased risks of technological and product homogeneity.

Downstream demand for cancer gene therapies is exhibiting the following trends: First, with the widespread adoption of precision medicine concepts, there is an increasing demand from patients and healthcare institutions for personalized treatment plans. Second, as efficacy data accumulates, more cancer patients, especially those with refractory or relapsed conditions, are considering gene therapies. Third, insurance companies and payers are gradually expanding coverage for gene therapies, reducing the financial burden on patients. Fourth, patients' concerns about treatment safety and quality of life are prompting research and development to focus more on controlling side effects and optimizing treatment regimens. Additionally, improvements in patient education and information access have enhanced acceptance of new therapies.

This report aims to provide a comprehensive presentation of the global market for Gene Therapies for Cancer Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Therapies for Cancer Treatment by region & country, by Type, and by Application.
The Gene Therapies for Cancer Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapies for Cancer Treatment.

Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral Vectors
Non-viral Vectors
Segment by Application
Solid Tumors
Hematologic Malignancies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Therapies for Cancer Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Therapies for Cancer Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Therapies for Cancer Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Gene Therapies for Cancer Treatment Product Introduction
1.2 Global Gene Therapies for Cancer Treatment Market Size Forecast (2020-2031)
1.3 Gene Therapies for Cancer Treatment Market Trends & Drivers
1.3.1 Gene Therapies for Cancer Treatment Industry Trends
1.3.2 Gene Therapies for Cancer Treatment Market Drivers & Opportunity
1.3.3 Gene Therapies for Cancer Treatment Market Challenges
1.3.4 Gene Therapies for Cancer Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gene Therapies for Cancer Treatment Players Revenue Ranking (2024)
2.2 Global Gene Therapies for Cancer Treatment Revenue by Company (2020-2025)
2.3 Key Companies Gene Therapies for Cancer Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gene Therapies for Cancer Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Gene Therapies for Cancer Treatment
2.6 Gene Therapies for Cancer Treatment Market Competitive Analysis
2.6.1 Gene Therapies for Cancer Treatment Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Gene Therapies for Cancer Treatment Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapies for Cancer Treatment as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Viral Vectors
3.1.2 Non-viral Vectors
3.2 Global Gene Therapies for Cancer Treatment Sales Value by Type
3.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Type (2020-2031)
3.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Solid Tumors
4.1.2 Hematologic Malignancies
4.2 Global Gene Therapies for Cancer Treatment Sales Value by Application
4.2.1 Global Gene Therapies for Cancer Treatment Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Gene Therapies for Cancer Treatment Sales Value, by Application (2020-2031)
4.2.3 Global Gene Therapies for Cancer Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Gene Therapies for Cancer Treatment Sales Value by Region
5.1.1 Global Gene Therapies for Cancer Treatment Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Gene Therapies for Cancer Treatment Sales Value by Region (2020-2025)
5.1.3 Global Gene Therapies for Cancer Treatment Sales Value by Region (2026-2031)
5.1.4 Global Gene Therapies for Cancer Treatment Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.2.2 North America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.3.2 Europe Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.4.2 Asia Pacific Gene Therapies for Cancer Treatment Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.5.2 South America Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value, 2020-2031
5.6.2 Middle East & Africa Gene Therapies for Cancer Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.3 United States
6.3.1 United States Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.3.2 United States Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.4.2 Europe Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.5.2 China Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.5.3 China Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.6.2 Japan Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.7.2 South Korea Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.8.2 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Gene Therapies for Cancer Treatment Sales Value, 2020-2031
6.9.2 India Gene Therapies for Cancer Treatment Sales Value by Type (%), 2024 VS 2031
6.9.3 India Gene Therapies for Cancer Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Biogen
7.1.1 Biogen Profile
7.1.2 Biogen Main Business
7.1.3 Biogen Gene Therapies for Cancer Treatment Products, Services and Solutions
7.1.4 Biogen Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.1.5 Biogen Recent Developments
7.2 Novartis
7.2.1 Novartis Profile
7.2.2 Novartis Main Business
7.2.3 Novartis Gene Therapies for Cancer Treatment Products, Services and Solutions
7.2.4 Novartis Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.2.5 Novartis Recent Developments
7.3 Gilead Sciences
7.3.1 Gilead Sciences Profile
7.3.2 Gilead Sciences Main Business
7.3.3 Gilead Sciences Gene Therapies for Cancer Treatment Products, Services and Solutions
7.3.4 Gilead Sciences Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.3.5 Gilead Sciences Recent Developments
7.4 Sarepta Therapeutics
7.4.1 Sarepta Therapeutics Profile
7.4.2 Sarepta Therapeutics Main Business
7.4.3 Sarepta Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
7.4.4 Sarepta Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.4.5 Sarepta Therapeutics Recent Developments
7.5 Sunway Biotech
7.5.1 Sunway Biotech Profile
7.5.2 Sunway Biotech Main Business
7.5.3 Sunway Biotech Gene Therapies for Cancer Treatment Products, Services and Solutions
7.5.4 Sunway Biotech Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.5.5 Sunway Biotech Recent Developments
7.6 SIBIONO
7.6.1 SIBIONO Profile
7.6.2 SIBIONO Main Business
7.6.3 SIBIONO Gene Therapies for Cancer Treatment Products, Services and Solutions
7.6.4 SIBIONO Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.6.5 SIBIONO Recent Developments
7.7 AnGes
7.7.1 AnGes Profile
7.7.2 AnGes Main Business
7.7.3 AnGes Gene Therapies for Cancer Treatment Products, Services and Solutions
7.7.4 AnGes Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.7.5 AnGes Recent Developments
7.8 Orchard Therapeutics
7.8.1 Orchard Therapeutics Profile
7.8.2 Orchard Therapeutics Main Business
7.8.3 Orchard Therapeutics Gene Therapies for Cancer Treatment Products, Services and Solutions
7.8.4 Orchard Therapeutics Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.8.5 Orchard Therapeutics Recent Developments
7.9 Human Stem Cells Institute
7.9.1 Human Stem Cells Institute Profile
7.9.2 Human Stem Cells Institute Main Business
7.9.3 Human Stem Cells Institute Gene Therapies for Cancer Treatment Products, Services and Solutions
7.9.4 Human Stem Cells Institute Gene Therapies for Cancer Treatment Revenue (US$ Million) & (2020-2025)
7.9.5 Human Stem Cells Institute Recent Developments
8 Industry Chain Analysis
8.1 Gene Therapies for Cancer Treatment Industrial Chain
8.2 Gene Therapies for Cancer Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gene Therapies for Cancer Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Gene Therapies for Cancer Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer